Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review
Open Access
- 17 December 2018
- journal article
- review article
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1-10
Abstract
Diabetes is one of the world’s most prevalent and serious non-communicable diseases (NCDs). It is a leading cause of death, disability and financial loss; moreover, it is identified as a major threat to global development. The chronic nature of diabetes and its related complications make it a costly disease. Estimating the total cost of an illness is a useful aid to national and international health policy decision making. The aim of this systematic review is to summarise the impact of the cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries, and to identify methodological gaps in measuring the cost-of-illness of type 2 diabetes mellitus. This systematic review considers studies that reported the cost-of-illness of type 2 diabetes in subjects aged 18 years and above in low and lower-middle income countries. The search engines MEDLINE, EMBASE, CINAHL, PSYCINFO and COCHRANE were used form date of their inception to September 2018. Two authors independently identified the eligible studies. Costs reported in the included studies were converted to US dollars in relation to the dates mentioned in the studies. The systematic search identified eight eligible studies conducted in low and lower-middle income countries. There was a considerable variation in the costs and method used in these studies. The annual average cost (both direct and indirect) per person for treating type 2 diabetes mellitus ranged from USD29.91 to USD237.38, direct costs ranged from USD106.53 to USD293.79, and indirect costs ranged from USD1.92 to USD73.4 per person per year. Hospitalization cost was the major contributor of direct costs followed by drug costs. Type 2 diabetes mellitus imposes a considerable economic burden which most directly affects the patients in low and lower-middle income countries. There is enormous scope for adding research-based evidence that is methodologically sound to gain a more accurate estimation of cost and to facilitate comparison between studies.Keywords
This publication has 41 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in IranPLOS ONE, 2011
- Globalization of DiabetesDiabetes Care, 2011
- Diabetes: cost of illness in NorwayBMC Endocrine Disorders, 2010
- Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methodsCurrent Medical Research and Opinion, 2010
- Role of Receptor-Interacting Protein 140 in human fat cellsBMC Endocrine Disorders, 2010
- Standards of Medical Care in Diabetes—2009Diabetes Care, 2009
- Cost of diabetes care in out-patient clinics of Karachi, PakistanBMC Health Services Research, 2007
- Health care utilization and costs in Saskatchewan's registered Indian population with diabetesBMC Health Services Research, 2007
- Cost-of-illness studies: fact or fiction?The Lancet, 1994